Cambridge Investment Research Advisors’s Intellia Therapeutics NTLA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$329K	Buy	25,702 +1,530	+6%	+$19.5K	﹤0.01%	3201
2025 Q4	$217K	Buy	24,172 +2,234	+10%	+$30.8K	﹤0.01%	3510
2025 Q3	$379K	Sell	21,938 -1,234	-5%	-$15.2K	﹤0.01%	2920
2025 Q2	$217K	Buy	23,172 +3,446	+17%	+$28.3K	﹤0.01%	3287
2025 Q1	$140K	Buy	19,726 +6,722	+52%	+$67.9K	﹤0.01%	3291
2024 Q4	$152K	Buy	13,004 +2,607	+25%	+$40.7K	﹤0.01%	3249
2024 Q3	$214K	Buy	+10,397	New	+$240K	﹤0.01%	3095
2023 Q3	–	Sell	-5,560	Closed	-$227K	–	3230
2023 Q2	$227K	Buy	+5,560	New	+$225K	﹤0.01%	2771
2022 Q4	–	Sell	-4,591	Closed	-$257K	–	3181
2022 Q3	$257K	Buy	4,591 +123	+3%	+$7.63K	﹤0.01%	2493
2022 Q2	$231K	Sell	4,468 -430	-9%	-$21.8K	﹤0.01%	2598
2022 Q1	$356K	Sell	4,898 -863	-15%	-$73.1K	﹤0.01%	2396
2021 Q4	$681K	Sell	5,761 -5,233	-48%	-$656K	﹤0.01%	1857
2021 Q3	$1.48M	Buy	10,994 +1,164	+12%	+$176K	0.01%	1260
2021 Q2	$1.59M	Buy	+9,830	New	+$765K	0.01%	1236